Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

Litwin, 2017, The Diagnosis and Treatment of Prostate Cancer: A Review, JAMA, 317, 2532, 10.1001/jama.2017.7248

Kwon, 2014, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial, Lancet Oncol., 15, 700, 10.1016/S1470-2045(14)70189-5

Chen, 2017, Elements of cancer immunity and the cancer-immune set point, Nature, 541, 321, 10.1038/nature21349

Huang, 2017, T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, 545, 60, 10.1038/nature22079

Verdegaal, 2016, Neoantigen landscape dynamics during human melanoma-T cell interactions, Nature, 536, 91, 10.1038/nature18945

June, 2017, Is autoimmunity the Achilles’ heel of cancer immunotherapy?, Nat. Med., 23, 540, 10.1038/nm.4321

Sadelain, 2017, Therapeutic T cell engineering, Nature, 545, 423, 10.1038/nature22395

Lim, 2017, The Principles of Engineering Immune Cells to Treat Cancer, Cell, 168, 724, 10.1016/j.cell.2017.01.016

Rabinovich, 2007, Immunosuppressive strategies that are mediated by tumor cells, Annu. Rev. Immunol., 25, 267, 10.1146/annurev.immunol.25.022106.141609

Joyce, 2015, T cell exclusion, immune privilege, and the tumor microenvironment, Science, 348, 74, 10.1126/science.aaa6204

Chong, 2017, PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR, Blood, 129, 1039, 10.1182/blood-2016-09-738245

Condomines, 2015, Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition, PLoS ONE, 10, e0130518, 10.1371/journal.pone.0130518

Siegel, 2003, Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer, Nat. Rev. Cancer, 3, 807, 10.1038/nrc1208

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Travis, 2014, TGF-β activation and function in immunity, Annu. Rev. Immunol., 32, 51, 10.1146/annurev-immunol-032713-120257

Ebner, 1993, Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor, Science, 260, 1344, 10.1126/science.8388127

Wieser, 1993, Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region, Mol. Cell. Biol., 13, 7239, 10.1128/MCB.13.12.7239

Gorelik, 2001, Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells, Nat. Med., 7, 1118, 10.1038/nm1001-1118

Gorelik, 2000, Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease, Immunity, 12, 171, 10.1016/S1074-7613(00)80170-3

Lucas, 2000, Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor, J. Exp. Med., 191, 1187, 10.1084/jem.191.7.1187

Zhang, 2005, Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer, Cancer Res., 65, 1761, 10.1158/0008-5472.CAN-04-3169

Donkor, 2011, T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine, Immunity, 35, 123, 10.1016/j.immuni.2011.04.019

Foster, 2008, Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor, J. Immunother., 31, 500, 10.1097/CJI.0b013e318177092b

Bollard, 2018, Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma, J. Clin. Oncol., 36, 1128, 10.1200/JCO.2017.74.3179

Vallabhajosula, 2016, Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody, Curr. Radiopharm., 9, 44, 10.2174/1874471008666150313114005

Bander, 2003, Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen, J. Urol., 170, 1717

Szklarczyk, 2015, STRING v10: protein-protein interaction networks, integrated over the tree of life, Nucleic Acids Res., 43, D447, 10.1093/nar/gku1003

Beretta, 2002, Central LIF gene therapy suppresses food intake, body weight, serum leptin and insulin for extended periods, Peptides, 23, 975, 10.1016/S0196-9781(02)00021-9

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3, 95ra73, 10.1126/scitranslmed.3002842

Ali, 2016, T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma, Blood, 128, 1688, 10.1182/blood-2016-04-711903

Golumbek, 1991, Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4, Science, 254, 713, 10.1126/science.1948050

Hung, 1998, The central role of CD4(+) T cells in the antitumor immune response, J. Exp. Med., 188, 2357, 10.1084/jem.188.12.2357

Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat. Med., 21, 581, 10.1038/nm.3838

Frigault, 2015, Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells, Cancer Immunol. Res., 3, 356, 10.1158/2326-6066.CIR-14-0186

Lee, 2011, In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy, Cancer Res., 71, 2871, 10.1158/0008-5472.CAN-10-0552

Wartewig, 2017, PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis, Nature, 552, 121, 10.1038/nature24649

Gust, 2017, Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells, Cancer Discov., 7, 1404, 10.1158/2159-8290.CD-17-0698

Fitzgerald, 2017, Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia, Crit. Care Med., 45, e124, 10.1097/CCM.0000000000002053

Maude, 2016, Current status of chimeric antigen receptor therapy for haematological malignancies, Br. J. Haematol., 172, 11, 10.1111/bjh.13792

Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol. Ther., 17, 1453, 10.1038/mt.2009.83

Kutner, 2009, Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors, Nat. Protoc., 4, 495, 10.1038/nprot.2009.22

Dupont, 1998, Power and sample size calculations for studies involving linear regression, Control. Clin. Trials, 19, 589, 10.1016/S0197-2456(98)00037-3